[Preclinical and clinical researches of lenvatinib mesylate (Lenvima capsule), a novel antitumor agent approved for thyroid cancer treatment]

Nihon Yakurigaku Zasshi. 2015 Nov;146(5):283-90. doi: 10.1254/fpj.146.283.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Angiogenesis Inhibitors / chemistry
  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / therapeutic use
  • Clinical Trials as Topic
  • Humans
  • Phenylurea Compounds / chemistry
  • Phenylurea Compounds / therapeutic use*
  • Protein Kinase Inhibitors / chemistry
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Kinases / chemistry
  • Protein Kinases / metabolism
  • Quinolines / chemistry
  • Quinolines / therapeutic use*
  • Thyroid Neoplasms / drug therapy*

Substances

  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Quinolines
  • Protein Kinases
  • lenvatinib